

RESEARCH

Open Access

# In vitro studies of the influence of glutamatergic agonists on the Na<sup>+</sup>,K<sup>+</sup>-ATPase and K<sup>+</sup>-p-nitrophenylphosphatase activities in the hippocampus and frontal cortex of rats

Marcos Brandão Contó\* and Marco Antonio Campana Venditti

## Abstract

**Background:** The overstimulation of excitatory glutamatergic neurotransmission and the inhibition of Na<sup>+</sup>,K<sup>+</sup>-ATPase enzymatic activity have both been implicated in neurotoxicity and are possibly related to the pathogenesis of epilepsy and neurodegenerative disorders. In the present study, we investigated whether glutamatergic stimulation by the glutamatergic agonists glutamate,  $\alpha$ -amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) modulates the Na<sup>+</sup>,K<sup>+</sup>-ATPase and the K<sup>+</sup>-p-nitrophenylphosphatase activities in the crude synaptosomal fraction of the hippocampus and the frontal cortex of rats.

**Results:** Our results demonstrated that these glutamatergic agonists did not influence the activities of Na<sup>+</sup>,K<sup>+</sup>-ATPase or K<sup>+</sup>-p-nitrophenylphosphatase in the brain structures analyzed. Assays with lower concentrations of ATP to analyze the preferential activity of the Na<sup>+</sup>,K<sup>+</sup>-ATPase isoform with high affinity for ATP did not show any influence either.

**Conclusions:** These findings suggest that under our experimental conditions, the stimulation of glutamatergic receptors does not influence the kinetics of the Na<sup>+</sup>,K<sup>+</sup>-ATPase enzyme in the hippocampus and frontal cortex.

**Keywords:** Na<sup>+</sup>,K<sup>+</sup>-ATPase, K<sup>+</sup>-p-nitrophenylphosphatase, Glutamate, AMPA, NMDA, Kainate, Frontal cortex, Hippocampus

## Background

Glutamate is the main excitatory neurotransmitter in the central nervous system [1], and the overstimulation of glutamatergic receptors, including the ionotropic receptors of N-methyl-D-aspartate (NMDA) and  $\alpha$ -amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid (AMPA), seems to be related to neuronal death caused by excitotoxicity [1,2]. Glutamate-induced neurotoxicity apparently underlies a variety of neurologic disorders, including epilepsy, Huntington's disease, Parkinson's disease and Alzheimer's disease [1]. Excessive accumulation of glutamate in the synaptic cleft can be due to higher glutamate release, lower uptake by pre-synaptic terminals and/or reverse transportation of glutamate from the pre-synaptic terminal towards

the synaptic cleft [2,3]. These processes can result from alterations in the Na<sup>+</sup> and K<sup>+</sup> concentration gradients between the intracellular and extracellular environments, which depend on the activity of the transmembrane enzyme Na<sup>+</sup>,K<sup>+</sup>-ATPase [4-6].

Na<sup>+</sup>,K<sup>+</sup>-ATPase is the enzyme responsible for the maintenance of low concentrations of Na<sup>+</sup> and high concentrations of K<sup>+</sup> in the intracellular environment, maintaining the resting potential and aiding in the reestablishment of this potential after neuronal depolarization [5]. Structurally, Na<sup>+</sup>,K<sup>+</sup>-ATPase is a heterotrimer formed by three subunits ( $\alpha_{1-4}$ ,  $\beta_{1-3}$  and  $\gamma$ ), and the kinetic properties of the isozymes are mainly determined by the  $\alpha$  subunit [7]. In the central nervous system,  $\alpha_1$  and  $\alpha_2$  function as the "housekeeping" isoforms, while the  $\alpha_3$  isoform is predominantly activated in situations involving high neuronal activity [8,9]. The inhibition of Na<sup>+</sup>, K<sup>+</sup>-ATPase activity by the glycoside ouabain elicits an excitatory effect leading to convulsions

\* Correspondence: mmmarcos@uol.com.br

Departamento de Psicobiologia, Universidade Federal de São Paulo, Escola Paulista de Medicina (UNIFESP/EPM), Rua Botucatu 862, 1° andar, Vila Clementino, São Paulo, SP 04023-062, Brazil

[10,11] and neuronal death through both apoptosis and necrosis [6]. Additionally, a deficiency in Na<sup>+</sup>,K<sup>+</sup>-ATPase activity has been linked to central nervous system disorders, including epilepsy and neurodegenerative diseases [4,6].

Several in vitro studies have been performed in an attempt to understand whether and how glutamatergic activation influences the kinetics of Na<sup>+</sup>,K<sup>+</sup>-ATPase in nervous tissue. The results, however, have not been consistent. Although some researchers have reported a stimulation of Na<sup>+</sup>,K<sup>+</sup>-ATPase enzymatic activity by glutamatergic agonists [12-14], others have demonstrated an inhibition of its activity [15-19] or neither stimulation nor inhibition [20,21]. It is worthwhile to mention that such contradictions may be due to some technical factors, including differences in brain tissues, tissue preparation and the biochemical assays performed; for example, <sup>42</sup>K<sup>+</sup> uptake has been analyzed using scintillation counting [12], Rb<sup>+</sup> uptake has been analyzed using atomic absorption spectroscopy [19] or scintillation counting [14] and inorganic phosphate release has been analyzed using spectrophotometry [15-17,20,21] and scintillation counting [13]. The results can also be discrepant depending on the family of glutamatergic receptor that is being stimulated [16,18,19].

Therefore, the present study sought to verify whether different concentrations of glutamate and the ionotropic glutamatergic agonists NMDA, AMPA and kainate would alter the kinetic behavior of Na<sup>+</sup>,K<sup>+</sup>-ATPase in the crude synaptosomal fraction of the hippocampus and the frontal cortex. These studies were performed using two different biochemical methods. The first method was a Na<sup>+</sup>,K<sup>+</sup>-ATPase assay involving the complete enzymatic reaction, including both Na<sup>+</sup>-dependent phosphorylation and K<sup>+</sup>-dependent dephosphorylation. The second method was a K<sup>+</sup>-*p*-nitrophenylphosphatase (K<sup>+</sup>-*p*-NPPase) assay involving only K<sup>+</sup>-dependent dephosphorylation. In the Na<sup>+</sup>,K<sup>+</sup>-ATPase assay, we performed studies with both saturating and sub-saturating concentrations of ATP. Under higher ATP concentrations, the activities of the isozymes

containing α<sub>1</sub>, α<sub>2</sub> and α<sub>3</sub> are indistinguishable. At lower ATP concentrations, isozymes containing α<sub>3</sub> can be preferentially assayed because they have a higher affinity for ATP [9]. Concomitant with these assays, we also investigated a putative influence of the glutamatergic agonists on the activities of ouabain-insensitive Mg<sup>2+</sup>-ATPase and Mg<sup>2+</sup>-*p*-nitrophenylphosphatase (Mg<sup>2+</sup>-*p*-NPPase).

## Results

Tables 1, 2, 3, 4, 5, and 6 show the values (mean ± standard deviation; N = 4-5/group) of K<sup>+</sup>-*p*-NPPase, Mg<sup>2+</sup>-*p*-NPPase, Na<sup>+</sup>,K<sup>+</sup>-ATPase and Mg<sup>2+</sup>-ATPase activities in the frontal cortex and hippocampus, respectively. The analysis of data using the unpaired Student's *t*-test demonstrated no statistical differences in the activities of K<sup>+</sup>-*p*-NPPase, Mg<sup>2+</sup>-*p*-NPPase, Na<sup>+</sup>,K<sup>+</sup>-ATPase and Mg<sup>2+</sup>-ATPase in the presence (experimental group) or absence (control group) of the glutamatergic agonists utilized. The control and the experimental groups correspond to the same tissue suspensions, and their enzymatic activities were all assayed simultaneously. Five different animals were used for each agonist concentration value (N<sub>TOTAL</sub>: 15 animals).

## Discussion

The literature has elucidated how alterations in Na<sup>+</sup>, K<sup>+</sup>-ATPase activity influence glutamatergic neurotransmission and how both of these elements are correlated to neurotoxicity, possibly contributing to a variety of neurological disorders, including epilepsy and neurodegenerative diseases. The excitatory effect and the apoptotic/necrotic processes elicited by the inhibition of Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in the central nervous system are probably due to several factors: (a) a decrease in the threshold to trigger subsequent action potentials because the accumulation of Na<sup>+</sup> leads to a lower intracellular electronegativity [6], (b) the increasing release of excitatory neurotransmitters

**Table 1 ATPases and *p*-NPPases activities in the frontal cortex in the presence or absence of 50 μM of glutamatergic agonists**

|           | K <sup>+</sup> - <i>p</i> NPPase<br>(10 mM) | Mg <sup>2+</sup> - <i>p</i> NPPase<br>(10 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase<br>(9 mM) | Mg <sup>2+</sup> -ATPase<br>(9 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase<br>(2 mM) | Mg <sup>2+</sup> -ATPase<br>(2 mM) |
|-----------|---|---|---|------------------------------------|---|------------------------------------|
| Control   | 149.7 ± 15.6                                | 56.48 ± 4.2                                   | 280.4 ± 33.8                                      | 158.6 ± 22.8                       | 129.5 ± 15.9                                      | 109.9 ± 7.4                        |
| Glutamate | 146.6 ± 25.7                                | 54.83 ± 4.2                                   | 299.7 ± 40.9                                      | 148.8 ± 26.2                       | 125.6 ± 12.1                                      | 107.9 ± 11.2                       |
| Control   | 143 ± 8.5                                   | 48.24 ± 3.1                                   | 302.8 ± 33.3                                      | 139.3 ± 10.7                       | 128.6 ± 25  | 61.93 ± 5.8                        |
| NMDA      | 148.1 ± 10.3                                | 45.39 ± 3.3                                   | 274.7 ± 38.7                                      | 148.2 ± 11.8                       | 134.4 ± 26.2                                      | 63.45 ± 5.8                        |
| Control   | 131.5 ± 6.5                                 | 49.74 ± 2.4                                   | 313.9 ± 51.6                                      | 178.2 ± 28.8                       | 138.6 ± 24.6                                      | 70.42 ± 3.8                        |
| AMPA      | 139.1 ± 6.7                                 | 48.64 ± 4.7                                   | 325.9 ± 36.7                                      | 180 ± 14.3                         | 146.8 ± 20.6                                      | 63.26 ± 8.7                        |
| Control   | 134.3 ± 10.5                                | 47.64 ± 5.1                                   | 310.7 ± 69.7                                      | 147.7 ± 15.2                       | 149.3 ± 13.2                                      | 81.58 ± 6.9                        |
| Kainate   | 142.9 ± 15.2                                | 45.4 ± 5.1                                    | 319.7 ± 51.9                                      | 130.3 ± 13.4                       | 144.6 ± 18.1                                      | 83.61 ± 9.8                        |

Values are expressed as mean ± standard deviation (5 animals/group). ATPases activities are expressed in nmol of P<sub>i</sub>/mg protein/min, and *p*-NPPases activities are expressed in nmol of *p*-nitrophenol/mg protein/min. The concentrations of the substrates are shown in parentheses.

**Table 2 ATPases and p-NPPases activities in the hippocampus in the presence or absence of 50 μM of glutamatergic agonists**

|           | K <sup>+</sup> -pNPPase (10 mM) | Mg <sup>2+</sup> -pNPPase (10 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (9 mM) | Mg <sup>2+</sup> -ATPase (9 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (2 mM) | Mg <sup>2+</sup> -ATPase (2 mM) |
|-----------|---------------------------------|-----------------------------------|--|---------------------------------|--|---------------------------------|
| Control   | 164.3 ± 5.8                     | 28.3 ± 6.5                        | 339.1 ± 89.4                                   | 209.5 ± 34.6                    | 198 ± 33.9                                     | 99.2 ± 7.4                      |
| Glutamate | 166.9 ± 8.7                     | 27.2 ± 5.4                        | 355.3 ± 70.6                                   | 197.9 ± 36.4                    | 202.8 ± 24.8                                   | 91.5 ± 8.9                      |
| Control   | 136.7 ± 13.4                    | 40.8 ± 4.7                        | 463.9 ± 67.1                                   | 159.3 ± 22.8                    | 201.2 ± 32.6                                   | 94.5 ± 6.7                      |
| NMDA      | 140 ± 12.5                      | 37.4 ± 7.1                        | 432.5 ± 27.7                                   | 156.9 ± 38.5                    | 190.4 ± 26.6                                   | 94.4 ± 6.5                      |
| Control   | 110.9 ± 12.7                    | 41.5 ± 7.6                        | 407.9 ± 61.9                                   | 238.8 ± 41.8                    | 200.6 ± 26.6                                   | 79.7 ± 10.3                     |
| AMPA      | 114.4 ± 10.5                    | 38.4 ± 5.6                        | 412.1 ± 74                                     | 221.5 ± 42.9                    | 188.3 ± 27.5                                   | 71.6 ± 6.3                      |
| Control   | 133 ± 5.2                       | 43.7 ± 7.8                        | 316 ± 119.4                                    | 144.9 ± 15.2                    | 205.4 ± 21                                     | 83.6 ± 12                       |
| Kainate   | 131.9 ± 11.8                    | 40.3 ± 8                          | 374.7 ± 82.3                                   | 124.8 ± 19.7                    | 205.5 ± 22.4                                   | 74.5 ± 7.8                      |

Values are expressed as mean ± standard deviation (4–5 animals/group). ATPases activities are expressed in nmol of P<sub>i</sub>/mg protein/min, and p-NPPases activities are expressed in nmol of p-nitrophenol/mg protein/min. The concentrations of the substrates are shown in parentheses.

into the synaptic cleft [22,23], (c) a reduction in the pre-synaptic uptake of glutamate from the synaptic cleft, a Na<sup>+</sup>-dependent process [2] and (d) the non-vesicular liberation of glutamate from the intracellular to the extracellular environment through the process of inverse transport by the glutamate transporters [2,3].

Nevertheless, it is still unclear whether and how Na<sup>+</sup>, K<sup>+</sup>-ATPase is influenced by the stimulation of glutamatergic receptors. It has been previously demonstrated that glutamatergic ionotropic agonists stimulate, in a dose-dependent manner, the total activity of Na<sup>+</sup>,K<sup>+</sup>-ATPase in primary cultures of rat cerebral neurons [12]. This result is in agreement with other studies using cultures of cerebellar neurons from rats [13] and in cultures of cerebral cortical astrocytes of mice [14], although these studies only used the neurotransmitter glutamate. However, a decrease in Na<sup>+</sup>,K<sup>+</sup>-ATPase activity after glutamatergic stimulation by NMDA receptor agonists has been observed in slices of rat cerebral cortex [19] and in cerebellar granule cells [16–18]. In another study, a decrease in Na<sup>+</sup>,K<sup>+</sup>-ATPase activity has been observed in rat brain

cortex synaptosomes using glutamate [15]. Other studies found neither stimulation nor inhibition of Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in the presence of different concentrations of glutamate in mouse brain synaptosomes [20] or in synaptosomes from the cerebral cortex from rats [21]. The enhancement of Na<sup>+</sup>,K<sup>+</sup>-ATPase activity could be interpreted as a negative feedback mechanism with a protective effect against glutamate neurotoxicity. On the other hand, the decrease in the Na<sup>+</sup>,K<sup>+</sup>-ATPase activity could be interpreted as a positive feedback mechanism that would potentiate glutamate neurotoxicity.

The current work indicated that the stimulation of glutamatergic receptors did not influence the Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in the frontal cortex and hippocampus, as analyzed using the K<sup>+</sup>-p-NPPase and Na<sup>+</sup>,K<sup>+</sup>-ATPase methods. Assays performed under high concentrations of Na<sup>+</sup>,K<sup>+</sup> and ATP simulated a situation of high neuronal activity [8,9], such as those elicited by glutamatergic hyperactivity, when the isozymes are indistinguishably activated. On the other hand, assays performed under lower concentrations of ATP simulated a situation of intense and prolonged glutamate-induced depolarization resulting in decreased

**Table 3 ATPases and p-NPPases activities in the frontal cortex in the presence or absence of 300 μM of glutamatergic agonists**

|           | K <sup>+</sup> -pNPPase (10 mM) | Mg <sup>2+</sup> -pNPPase (10 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (9 mM) | Mg <sup>2+</sup> -ATPase (9 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (2 mM) | Mg <sup>2+</sup> -ATPase (2 mM) |
|-----------|---------------------------------|-----------------------------------|--|---------------------------------|--|---------------------------------|
| Control   | 162.2 ± 10                      | 66.4 ± 3.3                        | 303.8 ± 32.4                                   | 124.4 ± 13.2                    | 154.0 ± 15.9                                   | 129.9 ± 16.1                    |
| Glutamate | 177.5 ± 15                      | 65.2 ± 5.8                        | 343.6 ± 72.2                                   | 104.8 ± 17.2                    | 149.2 ± 10.5                                   | 126.8 ± 10.7                    |
| Control   | 214.0 ± 23.2                    | 65.1 ± 3.1                        | 283.5 ± 30.4                                   | 192.8 ± 23.2                    | 134.6 ± 15.9                                   | 139.3 ± 7.8                     |
| NMDA      | 215.5 ± 16.1                    | 69.5 ± 6.7                        | 270.6 ± 78.9                                   | 174.3 ± 31.7                    | 130.7 ± 17.2                                   | 131.9 ± 12.5                    |
| Control   | 168.1 ± 13.6                    | 61.6 ± 2.4                        | 407.0 ± 53.4                                   | 219.7 ± 21.5                    | 159.5 ± 10.9                                   | 128.1 ± 13.6                    |
| AMPA      | 170.1 ± 13.6                    | 61.6 ± 5.4                        | 383.7 ± 79.8                                   | 195.4 ± 36                      | 146.3 ± 25                                     | 122.7 ± 10.1                    |
| Control   | 162.9 ± 6.9                     | 66.2 ± 3.6                        | 341.0 ± 39.8                                   | 192.0 ± 22.4                    | 161.0 ± 17.9                                   | 129.0 ± 14.5                    |
| Kainate   | 171.3 ± 9.4                     | 65.8 ± 7.6                        | 346.1 ± 80.3                                   | 166.8 ± 16.3                    | 148.8 ± 28.8                                   | 127.1 ± 10.5                    |

Values are expressed as mean ± standard deviation (5 animals/group). ATPases activities are expressed in nmol of P<sub>i</sub>/mg protein/min, and p-NPPases activities are expressed in nmol of p-nitrophenol/mg protein/min. The concentrations of the substrates are shown in parentheses.

**Table 4 ATPases and p-NPPases activities in the hippocampus in the presence or absence of 300 μM of glutamatergic agonists**

|           | K <sup>+</sup> -pNPPase (10 mM) | Mg <sup>2+</sup> -pNPPase (10 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (9 mM) | Mg <sup>2+</sup> -ATPase (9 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (2 mM) | Mg <sup>2+</sup> -ATPase (2 mM) |
|-----------|---------------------------------|-----------------------------------|--|---------------------------------|--|---------------------------------|
| Control   | 155.8 ± 7.4                     | 52.6 ± 1.8                        | 370.7 ± 26.2                                   | 205.4 ± 6.5                     | 152.9 ± 13.9                                   | 149.7 ± 16.8                    |
| Glutamate | 153.3 ± 6                       | 56.2 ± 4.9                        | 364.9 ± 32.9                                   | 189.4 ± 14.5                    | 166.6 ± 21.5                                   | 136.3 ± 11.4                    |
| Control   | 175.0 ± 10.5                    | 56.1 ± 2.4                        | 348.7 ± 45.2                                   | 211.6 ± 16.8                    | 156.1 ± 26.4                                   | 156.6 ± 13.6                    |
| NMDA      | 176.7 ± 13                      | 57.0 ± 3.3                        | 379.0 ± 21.7                                   | 195.8 ± 18.8                    | 143.1 ± 18.5                                   | 155.6 ± 18.5                    |
| Control   | 129.7 ± 10.3                    | 57.9 ± 5.8                        | 360.8 ± 24.1                                   | 239.6 ± 13.2                    | 146.1 ± 16.5                                   | 171.8 ± 23.5                    |
| AMPA      | 142.6 ± 16.3                    | 55.8 ± 3.1                        | 364.9 ± 19.7                                   | 230.0 ± 12.5                    | 146.2 ± 12.1                                   | 165.5 ± 12.1                    |
| Control   | 189.0 ± 10.5                    | 58.0 ± 3.3                        | 345.6 ± 32                                     | 237.0 ± 16.3                    | 180.1 ± 12.5                                   | 170.0 ± 22.6                    |
| Kainate   | 184.0 ± 9.8                     | 60.8 ± 2.9                        | 336.9 ± 44.7                                   | 221.2 ± 12.9                    | 163.8 ± 22.6                                   | 164.3 ± 20.6                    |

Values are expressed as mean ± standard deviation (5 animals/group). ATPases activities are expressed in nmol of P<sub>i</sub>/mg protein/min, and p-NPPases activities are expressed in nmol of p-nitrophenol/mg protein/min. The concentrations of the substrates are shown in parentheses.

intracellular ATP concentrations, such as in cases of epileptiform activity [24] and glutamate-induced neurotoxicity [25], and revealed a preferential activity of isozymes containing α<sub>3</sub>. However, we did not find any statistical differences. The lack of differences in our study is in agreement with previous reports in which glutamate did not alter the enzymatic activity in brain synaptosomes of mice [16] and the cerebral cortex of rats [17], although in this last case, the enzymatic reaction was conducted in the presence of a soluble brain fraction containing Na<sup>+</sup>, K<sup>+</sup>-ATPase modulators. In another study that utilized rat cerebral cortex slices, neither kainate nor AMPA changed Na<sup>+</sup>,K<sup>+</sup>-ATPase activity, although NMDA receptor agonists decreased it [14]. The agonists concentrations used in our study (50 μM, 300 μM and 1 mM) are compatible with the previous researches, in which were used glutamatergic agonists between micromolar and milimolar range [12-21]. Thus, it is highly unlikely that the lack of difference in our study is due to the agonists concentrations. It is possible that the age of the animals represents an important factor in the study. Although we performed the

enzymatic reaction with brain tissues from adult rats, the studies using the primary cultured cells were derived from rats with only a few days old.

### Conclusions

Therefore, the data obtained in the present work suggest that under the present experimental conditions, the stimulation of glutamatergic receptors does not influence the Na<sup>+</sup>,K<sup>+</sup>-ATPase activity in the frontal cortex and hippocampus. Further in vitro studies need to be performed, under different conditions, using different brain structures, tissue preparations, technical analysis and ages of the animals, in order to reach a better understanding of the relationship between glutamatergic activation and Na<sup>+</sup>,K<sup>+</sup>-ATPase activity.

### Material and methods

#### Animals

Subjects were naïve adult male Wistar rats aged three months and weighing approximately 350 g. They were housed in groups of three to four rats per cage (60 x 50 x

**Table 5 ATPases and p-NPPases activities in the frontal cortex in the presence or absence of 1 mM of glutamatergic agonists**

|           | K <sup>+</sup> -pNPPase (10 mM) | Mg <sup>2+</sup> -pNPPase (10 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (9 mM) | Mg <sup>2+</sup> -ATPase (9 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase (2 mM) | Mg <sup>2+</sup> -ATPase (2 mM) |
|-----------|---------------------------------|-----------------------------------|--|---------------------------------|--|---------------------------------|
| Control   | 169.6 ± 19.4                    | 53.7 ± 3.3                        | 289.4 ± 22.4                                   | 138.7 ± 14.7                    | 173.0 ± 31.7                                   | 192.8 ± 22.3                    |
| Glutamate | 167.2 ± 20.3                    | 55.0 ± 3.1                        | 255.2 ± 35.3                                   | 129.5 ± 5.8                     | 162.4 ± 6.5                                    | 170.5 ± 24.8                    |
| Control   | 169.4 ± 8.9                     | 53.4 ± 3.6                        | 305.7 ± 22.1                                   | 159.5 ± 18.5                    | 161.6 ± 10.9                                   | 188.4 ± 16.1                    |
| NMDA      | 168.5 ± 3.1                     | 53.8 ± 2.4                        | 275.3 ± 38.9                                   | 146.7 ± 7.1                     | 157.5 ± 17.7                                   | 176.8 ± 12.3                    |
| Control   | 172.5 ± 11.2                    | 41.7 ± 2.9                        | 265.2 ± 36.4                                   | 202.4 ± 12.7                    | 141.4 ± 15.9                                   | 165.5 ± 24.3                    |
| AMPA      | 174.2 ± 17.4                    | 41.2 ± 1.8                        | 304.0 ± 21                                     | 213.4 ± 17.7                    | 136.7 ± 19.4                                   | 167.6 ± 12.1                    |
| Control   | 165.3 ± 18.5                    | 57.6 ± 1.8                        | 296.8 ± 46.9                                   | 205.8 ± 17.7                    | 154.6 ± 13.4                                   | 166.7 ± 12.5                    |
| Kainate   | 179.9 ± 23.7                    | 55.5 ± 6.9                        | 257.8 ± 35.1                                   | 189.6 ± 13.4                    | 149.3 ± 27.7                                   | 163.7 ± 11.6                    |

Values are expressed as mean ± standard deviation (5 animals/group). ATPases activities are expressed in nmol of P<sub>i</sub>/mg protein/min, and p-NPPases activities are expressed in nmol of p-nitrophenol/mg protein/min. The concentrations of the substrates are shown in parentheses.

**Table 6 ATPases and *p*-NPPases activities in the hippocampus in the presence or absence of 1 mM of glutamatergic agonists**

|           | K <sup>+</sup> - <i>p</i> NPPase<br>(10 mM) | Mg <sup>2+</sup> - <i>p</i> NPPase<br>(10 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase<br>(9 mM) | Mg <sup>2+</sup> -ATPase<br>(9 mM) | Na <sup>+</sup> ,K <sup>+</sup> -ATPase<br>(2 mM) | Mg <sup>2+</sup> -ATPase<br>(2 mM) |
|-----------|---|---|---|------------------------------------|---|------------------------------------|
| Control   | 140.8 ± 19.4                                | 52.6 ± 4.5                                    | 286.6 ± 25.3                                      | 205.7 ± 25.9                       | 146.7 ± 14.5                                      | 141.7 ± 14.5                       |
| Glutamate | 143.2 ± 9.8                                 | 52.5 ± 3.3                                    | 271.2 ± 36  | 190.0 ± 14.5                       | 136.2 ± 14.7                                      | 145.4 ± 18.1                       |
| Control   | 107.2 ± 7.6                                 | 54.9 ± 5.8                                    | 327.2 ± 22.1                                      | 211.8 ± 22.1                       | 137.9 ± 12.1                                      | 149.4 ± 10.9                       |
| NMDA      | 109.3 ± 9.2                                 | 56.7 ± 3.3                                    | 320.3 ± 32.4                                      | 204.6 ± 16.1                       | 125.5 ± 10  | 150.1 ± 4.9                        |
| Control   | 163.1 ± 15.2                                | 49.7 ± 6                                      | 300.6 ± 18.5                                      | 192.0 ± 28.6                       | 156.2 ± 12.7                                      | 153.3 ± 17.7                       |
| AMPA      | 159.5 ± 21.2                                | 50.9 ± 3.3                                    | 304.7 ± 15.6                                      | 187.3 ± 8.9                        | 155.3 ± 21  | 150.3 ± 15.4                       |
| Control   | 134.0 ± 11.6                                | 52.5 ± 4.7                                    | 290.7 ± 15.6                                      | 191.9 ± 20.1                       | 154.2 ± 18.8                                      | 149.6 ± 18.1                       |
| Kainate   | 134.8 ± 10.1                                | 54.1 ± 1.6                                    | 276 ± 31.7  | 172.3 ± 13.2                       | 137.3 ± 13  | 148.6 ± 13.6                       |

Values are expressed as mean ± standard deviation (5 animals/group). ATPases activities are expressed in nmol of P<sub>i</sub>/mg protein/min, and *p*-NPPases activities are expressed in nmol of *p*-nitrophenol/mg protein/min. The concentrations of the substrates are shown in parentheses.

22 cm) in a temperature-controlled environment (23 ± 2°C) with a 12:12 h light–dark cycle (lights on from 7:00 a.m. to 7:00 p.m.) with ad lib food and water. This work was approved by our institution's Ethics Committee on Animal Research (Proc. 0851/10).

#### Assays of the enzymatic activities of K<sup>+</sup>-*p*-NPPase and Mg<sup>2+</sup>-*p*-NPPase

The activity of Na<sup>+</sup>,K<sup>+</sup>-ATPase occurs through two fundamental steps, the Na<sup>+</sup>-dependent phosphorylation and the K<sup>+</sup>-dependent dephosphorylation. While the activity of Na<sup>+</sup>,K<sup>+</sup>-ATPase includes both of these steps, which result in the hydrolysis of the natural substrate ATP into ADP and inorganic phosphate (P<sub>i</sub>), the activity of K<sup>+</sup>-*p*-NPPase consists of the hydrolysis of the artificial substrate *p*-nitrophenylphosphate into *p*-nitrophenol and P<sub>i</sub> and corresponds to K<sup>+</sup>-dependent dephosphorylation by Na<sup>+</sup>,K<sup>+</sup>-ATPase.

The animals were sacrificed by decapitation. The brains were carefully removed and washed with ice-cold 0.9% (w/v) saline solution, and the frontal cortex and hippocampus were rapidly dissected on a cooled petri dish on crushed ice. After weighing, these structures were stored at –20°C until the preparation of homogenates. The K<sup>+</sup>-*p*-nitrophenylphosphatase assay was performed as previously described [26]. The homogenates of the brain structures were prepared in ice-cold 0.32 M sucrose (pH 7.0) (2.5% w/v) using a glass homogenizer tube and a motor-driven Teflon pestle. The homogenates were centrifuged at 900 x g for 10 min at 4°C, and the resulting supernatants were centrifuged at 23,000 x g for 20 min at 4°C. The supernatants were discarded, and the pellets were resuspended in 50 mM Tris/HCl (pH 7.4) containing 1 mM EDTA and centrifuged at 23,000 x g for 20 min at 4°C. The supernatants were discarded, and the pellets were resuspended in 50 mM Tris/HCl (pH 7.4) containing 1 mM EDTA. In small glass test tubes, the total *p*-nitrophenylphosphatase activity was assayed in an

incubation medium consisting of 40–60 µg protein of the homogenate, 50 mM Tris/HCl (pH 7.4), 5 mM MgCl<sub>2</sub>, 10 mM *p*-nitrophenylphosphate and 10 mM KCl in the presence or absence of glutamate (Sigma<sup>®</sup>), kainate (Sigma<sup>®</sup>), AMPA (Sigma<sup>®</sup>) or NMDA (Sigma<sup>®</sup>) (50 µM, 300 µM or 1 mM), resulting in a final volume of 100 µL. The ouabain-insensitive Mg<sup>2+</sup>-*p*-NPPase activity was determined in a similar medium that was deficient in K<sup>+</sup>. The reactions were incubated in a shaking water bath for 10 min at 37°C. The reaction was stopped by adding 100 µL trichloroacetic acid (10% w/v), the test tubes were centrifuged, and a 100-µL aliquot of the cleared supernatant was transferred into a test tube containing 600 µL of 1 M Tris-base solution. The samples were read in a spectrophotometer at a wavelength of 410 nm. K<sup>+</sup>-*p*-NPPase activity was calculated by subtracting the reaction in the absence of KCl from the reaction in presence of KCl. A standard curve was calculated using six distinct amounts of *p*-nitrophenol ranging from 10–120 nmol. The protein in the homogenates was quantified using bovine serum albumin as a standard [27]. The final results are expressed as nmol of *p*-nitrophenol released/mg protein/min.

#### Assays of the enzymatic activities of Na<sup>+</sup>,K<sup>+</sup>-ATPase and Mg<sup>2+</sup>-ATPase

The Na<sup>+</sup>,K<sup>+</sup>-ATPase assays were performed as previously described [28], with some modifications. The homogenates of the brain structures were the same as those used for the K<sup>+</sup>-*p*-nitrophenylphosphatase assays. In small glass test tubes, the total ATPase activity was assayed in an incubation medium consisting of 8–12 µg protein of the homogenate, 150 mM Tris/HCl (pH 7.4), 4 mM MgCl<sub>2</sub>, 9 mM (or 2 mM) ATP, 70 mM NaCl and 40 mM KCl in the presence or absence of glutamate, kainate, AMPA or NMDA (50 µM, 300 µM or 1 mM), resulting in a final volume of 90 µL. The ouabain-insensitive Mg<sup>2+</sup>-ATPase activity was determined

in a similar medium that was deficient in Na<sup>+</sup> and K<sup>+</sup> but contained 1 mM ouabain. The reactions were incubated in a shaking water bath for 30 min at 37°C. The reaction was stopped by adding 20 µL trichloroacetic acid (30% w/v), the test tubes were centrifuged, and a 50 µL aliquot of the cleared supernatant was used for determination of released orthophosphate [29]. The samples were read in a spectrophotometer at a wavelength of 820 nm. Na<sup>+</sup>, K<sup>+</sup>-ATPase activity was calculated by subtracting the reaction in the absence of NaCl and KCl and containing ouabain from the reaction in the presence of NaCl and KCl and lacking ouabain. A standard curve was calculated using three distinct amounts of Na<sub>2</sub>HPO<sub>4</sub> ranging from 25–100 nmol (Additional files 1, 2, 3, 4, and 5). The protein in the homogenates was quantified using bovine serum albumin as a standard [27]. The final results are expressed as nmol of P<sub>i</sub> released/mg protein/min.

### Statistical analysis

The unpaired Student's t-test was used to compare the activities of Na<sup>+</sup>,K<sup>+</sup>-ATPase, K<sup>+</sup>-p-NPPase, Mg<sup>2+</sup>-p-NPPase and Mg<sup>2+</sup>-ATPase in the presence and absence of the glutamatergic agonists. The significance level was set at p ≤ 0.05 for all statistical tests. The statistical analyses were performed using Statistica version 6.1. and Prism 3.0.

### Additional files

**Additional file 1: Standard curve depicting the linear relationship between absorbance and amounts of P<sub>i</sub> (25, 50 and 100 nmoles).**

This interval comprises the amount of P<sub>i</sub> released in our enzymatic assay.

**Additional file 2: Standard curve depicting the linear relationship between absorbance and amounts of P<sub>i</sub> (25, 50 and 100 nmoles).**

This interval comprises the amount of P<sub>i</sub> released in our enzymatic assay.

**Additional file 3: Standard curve depicting the linear relationship between absorbance and amounts of P<sub>i</sub> (25, 50 and 100 nmoles).**

This interval comprises the amount of P<sub>i</sub> released in our enzymatic assay.

**Additional file 4: Standard curve depicting the linear relationship between absorbance and amounts of P<sub>i</sub> (25, 50 and 100 nmoles).**

This interval comprises the amount of P<sub>i</sub> released in our enzymatic assay.

**Additional file 5: Standard curve depicting the linear relationship between absorbance and amounts of P<sub>i</sub> (25, 50 and 100 nmoles).**

This interval comprises the amount of P<sub>i</sub> released in our enzymatic assay.

### Competing interests

The authors declare that they have no competing interest.

### Acknowledgments

We thank Ricardo Marques for his technical assistance. This research was supported by Associação Fundo de Incentivo à Pesquisa (AFIP). M.B. Contó was the recipient of a fellowship from AFIP.

### Authors' contributions

MBC carried out the biochemical assays, performed the statistical analysis, participated in the design of the study and drafted the manuscript. MACV participated in the experimental design and in the conceiving of the study. The authors read and approved the final manuscript.

Received: 17 January 2012 Accepted: 24 April 2012

Published: 10 May 2012

### References

1. Meldrum BS: Glutamate as a neurotransmitter in the brain: review of physiology and pathology. *J Nut* 2000, **130**:1007S–1015S.
2. Camacho A, Massieu L: Role of glutamate transporters in the clearance and release of glutamate during ischemia and its relation to neuronal death. *Arch Med Res* 2006, **37**:11–18.
3. Li S, Stys PK: Na<sup>+</sup>K<sup>+</sup>-ATPase inhibition and depolarization induce glutamate release via reverse Na<sup>+</sup>-dependent transport in spinal cord of white matter. *Neurosci* 2001, **107**(4):675–683.
4. Rose AM, Valdes R: Understanding the sodium pump and its relevance to disease. *Clin Chem* 1994, **40**(9):1674–1685.
5. Therien A, Blostein R: Mechanisms of sodium pump regulation. *Am J Physiol Cell Physiol* 2000, **279**:C541–C566.
6. Yu SP: Na<sup>+</sup>, K<sup>+</sup>-ATPase: the new face of an old player in pathogenesis and apoptotic/hybrid cell death. *Biochem Pharmacol* 2003, **66**:1601–1609.
7. Mobasher A, Avila J, Cózar-Castellano I, Brownleader MD, Trevan M, Francis MJ, Lamb JF, Martin-Vasallo P: Na<sup>+</sup>, K<sup>+</sup>-ATPase isozyme diversity; comparative biochemistry and physiological implications of novel functional interactions. *Biosci Rep* 2002, **20**(2):51–91.
8. Blanco G, Mercer RW: Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. *Am J Physiol* 1998, **275**:F633–F650.
9. Jewell EA, Lingrel JB: Comparison of the substrate dependence properties of the rat Na, K-ATPase α1, α2 and α3 isoforms expressed in HeLa Cells. *J Biol Chem* 1991, **266**(25):16925–16930.
10. Bignami A, Palladini G: Experimentally produced cerebral status spongiosus and continuous pseudorhythmic electroencephalographic discharges with a membrane-ATPase inhibitor in the rat. *Nature* 1966, **209**:413–414.
11. Pedley TA, Zuckermann EC, Glaser GH: Epileptogenic effects of localized ventricular perfusion of ouabain on dorsal hippocampus. *Exp Neurol* 1969, **25**:207–219.
12. Inoue N, Soga T, Kato T: Glutamate receptors mediate regulation of Na pump isoform activities in neurons. *Neuroreport* 1999, **10**:3289–3293.
13. Marcaida G, Kosenko E, Miñana M-D, Grisolia S, Felipe V: Glutamate induces a calcineurin-mediated dephosphorylation of Na<sup>+</sup>, K<sup>+</sup>-ATPase that results in its activation in cerebellar neurons in culture. *J Neurochem* 1996, **66**(1):99–104.
14. Pellerin L, Magistretti PJ: Glutamate uptake stimulates Na<sup>+</sup>, K<sup>+</sup>-ATPase activity in astrocytes via activation of a distinct subunit highly sensitive to ouabain. *J Neurochem* 1997, **69**(5):2132–2137.
15. Avrova NF, Victorov IV, Tyurin VA, Zakharova IO, Sokolova TV, Andreeva NA, et al: Inhibition of glutamate-induced intensification of free radical reactions by gangliosides: possible role in their protective effect in rat cerebellar granule cells and brain synaptosomes. *Neurochem Res* 1998, **23**(7):945–952.
16. Boldyrev A, Bulygina E, Carpenter D, Schonher W: Glutamate receptors communicate with Na<sup>+</sup>, K<sup>+</sup>-ATPase in rat cerebellum granule cells. *J Mol Neurosci* 2003, **21**:213–222.
17. Bulygina ER, Yu L, Boldyrev AA: Activation of glutamate receptors inhibits Na/K-ATPase of cerebellum granule cells. *Biochem (Moscow)* 2002, **67**(9):1001–1005.
18. Bulygina E, Gerasimova O, Boldyrev A: Glutamate receptors regulate Na/K-ATPase in cerebellum neurons. *Ann NY Acad Sci* 2003, **986**:611–613.
19. Nanitsos EK, Acosta GB, Saihara Y, Stanton D, Liao LP, Shin JW, Rae C, Balcar VJ: Effects of glutamate transport substrates and glutamate receptor ligands on the activity of Na<sup>+</sup>/K<sup>+</sup>-ATPase in brain tissue in vitro. *Clin Exp Pharmacol Physiol* 2004, **31**:762–769.
20. Desaijah D, Ho IK: Kinetics of catecholamine sensitive Na<sup>+</sup>-K<sup>+</sup> ATPase activity in mouse brain synaptosomes. *Biochem Pharmacol* 1977, **26**:2029–2035.
21. de Rodríguez Lores Arnaiz G, de Antonelli Gómez Lima M: The effect of several neurotransmitter substances on nerve ending membrane ATPase. *Acta Physiol Latinoam* 1981, **6**:43–48.
22. Cousin MA, Nicholls DG, Pocock JM: Modulation of ion gradients and glutamate release in cultured cerebellar granule cells by ouabain. *J Neurochem* 1995, **64**(5):2097–2104.

23. Veldhuis W, van der Stelt M, Delmas F, Gillet B, Veldink GA, Vliegenthart JFG, Nicolay K, Bär PR: **In vivo excitotoxicity induced by ouabain, a Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibitor.** *J Cereb Blood Flow Metab* 2003, **23**:62–74.
24. Dale N, Frenguelli BG: **Release of adenosine and ATP during ischemia and epilepsy.** *Curr Neuropharmacol* 2009, **7**:160–179.
25. Tsuji K, Nakamura Y, Ogata T, Shibata T, Kataoka K: **Rapid decrease in ATP content without recovery phase during glutamate-induced cell death in cultured spinal neurons.** *Brain Res* 1994, **662**:289–292.
26. Alves R, de Carvalho JGB, Benedito MAC: **High and low rearing subgroups of rats selected in the open Field differ in the activity of K<sup>+</sup>-stimulated-*p*-nitrophenylphosphatase in the hippocampus.** *Brain Res* 2005, **1058**:178–182.
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: **Protein measurement with the Folin phenol reagent.** *J Biol Chem* 1951, **193**:265–275.
28. Albers RW, de Rodrigues Lores Arnaiz G, De Robertis E: **Sodium-potassium-activated ATPase and potassium-activated *p*-nitrophenyl-phosphatase: a comparison of their subcellular localization in rat brain.** *Proc Natl Acad Sci USA* 1965, **53**:557–564.
29. Lowry OH, Lopez JA: **The determination of inorganic phosphate in the presence of labile phosphate esters.** *J Biol Chem* 1946, **162**:421–428.

doi:10.1186/1477-5751-11-12

**Cite this article as:** Contó and Venditti: In vitro studies of the influence of glutamatergic agonists on the Na<sup>+</sup>,K<sup>+</sup>-ATPase and K<sup>+</sup>-*p*-nitrophenylphosphatase activities in the hippocampus and frontal cortex of rats. *Journal of Negative Results in BioMedicine* 2012 **11**:12.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

 **BioMed** Central